Back To Search Instructions
Protocols
8 protocol(s) meet the specified criteria
Disease Site: Melanoma, skin
Protocol No.TitleStatus
AMG232-20120238A Phase 1b/2 Study Evaluation of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 232 Combined with Trametinib and Dabrafenib or Trametinib in Adult Subjects with Metastatic Cutaneous MelanomaOpen
CA209-204Multi-Center Phase 2 Open-Label Study to Evaluate Safety and Efficacy in Subjects with Melanoma Metastatic to the Brain treated with Nivolumab in Combination with Ipilimumab followed by Nivolumab MonotherapyOpen
ECOG1609-CIRBA Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Vs High Dose Interferon alpha2b for Resected High-Risk Melanoma Open (affiliates only)
LCCC0824Tissue Procurement For Hematolymphoid ConditionsOpen
MCC-16962A Phase I Trial of Dose Escalation of Metformin in Combination with Vincristine, Irinotecan, and Temozolomide in Children with Relapsed or Refractory Solid TumorsOpen
ML28897PRO/02My Pathway: An Open-Label Phase IIA Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, and Vismodegib in Patients who have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Predictive of Response to one of these Agents.Open
NCI9922A Phase 2 Study of Ibrutinib (PCI-32765) in Refractory Distant Metastatic Cutaneous Melanoma: Correlation of Biomarkers with Response and Resistance Open
S1404-CIRB-MK-3475-053S1404: A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma Open